



## CNS Therapeutics That Target Neuronal Ceroid-Lipofuscinoses and Thioesterase Deficiency Disorders

### Summary (1024-character limit)

The Eunice Kennedy Shriver National Institute of Child Health and Human Development seeks licensing or co-development partners for therapeutic compounds to treat lysosomal storage disorders.

### NIH Reference Number

E-157-2011

### Product Type

- Therapeutics

### Keywords

- Non-toxic derivative of hydroxylamine
- Neuronal Ceroid-Lipofuscinoses (NCL)
- lysosomal storage disorders (LSD)
- Palmitoyl-protein thioesterase
- lysosome

### Collaboration Opportunity

This invention is available for licensing and co-development.

### Contact

- John D. Hewes  
NCI - National Cancer Institute

240-276-5515

[John.Hewes@nih.gov](mailto:John.Hewes@nih.gov)

### Description of Technology

Clinically known as Neuronal Ceroid-Lipofuscinoses (NCL), Batten disease, is a rare neuron killing disease and one of the lysosomal storage disorders (LSDs). It is associated with a mutation or lack of palmitoyl-protein thioesterase-1 (PPT1) gene. It manifests very early in a child's life causing absence of brain activity as early as 4 years of age.

[Dr. Mukherje of NICHD](#) has discovered and developed N-t-BuHA, a chemical derivative of hydroxylamine that mimics the action of PPT1 enzyme. Compared to hydroxylamine, N-t-BuHA has been shown to be non-toxic in mice expressing batten disease. In addition, NtBuHA exhibited potent antioxidant property and extended the life of the diseased mice. NtBuHA has shown promising



therapeutic potential to treat NCL-LSDs.

### Potential Commercial Applications

- Small molecule therapeutic for neuronal ceroid-lipofuscinosis
- Small molecule to treat or prevent thioesterase deficiency disorders.

### Competitive Advantages

- First of its kind to treat INCL and other LSD
- Non-toxic derivative therapeutic against thioesterase deficiency disorders

### Inventor(s)

Anil Baran Mukherjee (NICHD), Chinmoy Sarkar (NICHD), Zhongjian Zhang (NICHD)

### Development Stage

- Pre-clinical (in vivo)

### Publications

Sarkar, C., et al. [[PMID 24056696](#)]

### Patent Status

- **U.S. Patent Filed:** U.S. Patent Application Number 14/110,393, Filed 07 Oct 2013
- **Foreign Filed:** EP - Patent Application 12716889.6, Filed 07 Oct 2013